Molecular understanding of hyperglycemia's adverse effects for diabetic complications.
暂无分享,去创建一个
[1] A J Adams,et al. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. , 1999, Investigative ophthalmology & visual science.
[2] H. Bohlen,et al. Arteriolar nitric oxide concentration is decreased during hyperglycemia-induced betaII PKC activation. , 2001, American journal of physiology. Heart and circulatory physiology.
[3] F. Ziyadeh. The extracellular matrix in diabetic nephropathy. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] Y. Akagi,et al. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. , 1990, Archives of ophthalmology.
[5] V. Monnier,et al. Accelerated age-related browning of human collagen in diabetes mellitus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[6] G. King,et al. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus , 1997, Journal of Molecular Medicine.
[7] B. Tesfamariam. Free radicals in diabetic endothelial cell dysfunction. , 1994, Free radical biology & medicine.
[8] R. Kikkawa,et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. , 2001, Diabetes care.
[9] E. Feldman,et al. Complications: Neuropathy, Pathogenetic Considerations , 1992, Diabetes Care.
[10] G. Schmid-Schönbein,et al. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. , 1991, The American journal of pathology.
[11] S. Bursell,et al. Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor , 1996, Science.
[12] S. Tesfaye,et al. Vascular factors in diabetic neuropathy , 1994, Diabetologia.
[13] S. Shatadal,et al. Protein kinase C-β mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells , 2000 .
[14] Y. Kaneda,et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.
[15] A. Schmidt,et al. RAGE: A New Target for the Prevention and Treatment of the Vascular and Inflammatory Complications of Diabetes , 2000, Trends in Endocrinology & Metabolism.
[16] E. Kohner,et al. Intracellular protein glycation in cultured retinal capillary pericytes and endothelial cells exposed to high-glucose concentration. , 1999, Cellular and molecular biology.
[17] T. Cruz,et al. Involvement of Reactive Oxygen Species in Cytokine and Growth Factor Induction of c-fos Expression in Chondrocytes(*) , 1995, The Journal of Biological Chemistry.
[18] Y. Hinokio,et al. Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. , 1999, Diabetes research and clinical practice.
[19] V. Ferrans,et al. Requirement for Generation of H2O2 for Platelet-Derived Growth Factor Signal Transduction , 1995, Science.
[20] S. Devaraj,et al. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. , 2001, Clinical chemistry.
[21] G. King,et al. d-Alpha-tocopherol prevents the hyperglycemia induced activation of diacylglycerol (DAG)-protein kinase C (PKC) pathway in vascular smooth muscle cell by an increase of DAG kinase activity. , 1999, Diabetes research and clinical practice.
[22] J. Tang,et al. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. , 2001, Diabetes.
[23] L. Aiello,et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. , 1999, Diabetes care.
[24] M. Brownlee,et al. Advanced protein glycosylation in diabetes and aging. , 1995, Annual review of medicine.
[25] Hidehiro Ishii,et al. Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitor , 1997, Diabetes.
[26] L. Aiello,et al. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. , 1997, Diabetes/metabolism reviews.
[27] J. Lunec,et al. Vitamin C metabolites and microangiopathy in diabetes mellitus. , 1987, Diabetes research.
[28] A. Schmidt,et al. Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.
[29] S. Bursell,et al. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. , 1993, The American journal of physiology.
[30] V. Natarajan,et al. Hydroperoxide-induced diacylglycerol formation and protein kinase C activation in vascular endothelial cells. , 1993, Archives of biochemistry and biophysics.
[31] J. Nyengaard,et al. Hyperglycemic Pseudohypoxia and Diabetic Complications , 1993, Diabetes.
[32] R. Myers,et al. Galactose neuropathy: Impact of chronic endoneurial edema on nerve blood flow , 1984, Annals of neurology.
[33] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[34] S. Basili,et al. Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. , 1997, Metabolism: clinical and experimental.
[35] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[36] S. Kawashima,et al. Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus , 1999, The British journal of ophthalmology.
[37] P. Low,et al. Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy , 1995, Experimental Neurology.
[38] C. Whiteside,et al. Altered expression and subcellular localization of diacylglycerol-sensitive protein kinase C isoforms in diabetic rat glomerular cells. , 1998, Diabetes.
[39] A. Samii,et al. Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats , 1999, Neuroscience Letters.
[40] P. Dyck,et al. Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[41] C. Szabó,et al. Rapid Reversal of the Diabetic Endothelial Dysfunction by Pharmacological Inhibition of Poly(ADP-Ribose) Polymerase , 2001, Circulation research.
[42] Norman Fleischer,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. , 1993 .
[43] S. Srinivasan,et al. Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. , 2000, Diabetes.
[44] H. Brady,et al. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. , 2000, Kidney international.
[45] K. Moon,et al. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. , 2001, The Journal of laboratory and clinical medicine.
[46] J. Baynes,et al. Pathways of formation of glycoxidation products during glycation of collagen. , 1995, Biochemistry.
[47] B. Gallacher,et al. Glucose-Induced Protein Kinase C Activation Regulates Vascular Permeability Factor mRNA Expression and Peptide Production by Human Vascular Smooth Muscle Cells In Vitro , 1997, Diabetes.
[48] S. Bain,et al. Genetics of diabetic nephropathy. , 2001, Best practice & research. Clinical endocrinology & metabolism.
[49] J. Crowley,et al. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. , 1999, The Journal of clinical investigation.
[50] H. Tritschler,et al. Lipoic Acid Improves Nerve Blood Flow, Reduces Oxidative Stress, and Improves Distal Nerve Conduction in Experimental Diabetic Neuropathy , 1995, Diabetes Care.
[51] J. Baynes,et al. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. , 1995, Biochemistry.
[52] E M Kohner,et al. Role of Blood Flow and Impaired Autoregulation in the Pathogenesis of Diabetic Retinopathy , 1995, Diabetes.
[53] P. Durrington,et al. Paraoxonase and coronary heart disease. , 1998, Atherosclerosis. Supplements.
[54] J. Williamson,et al. Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. , 2001 .
[55] G. King,et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo : a specific vascular action of insulin. , 2000, Circulation.
[56] J. Kinoshita. Mechanisms initiating cataract formation. Proctor Lecture. , 1974, Investigative ophthalmology.
[57] M. Cotter,et al. Effects of diabetes on reactivity of sciatic vasa nervorum in rats. , 1997, Journal of diabetes and its complications.
[58] N. Hotta,et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. , 1999, Diabetes.
[59] K. Gabbay,et al. Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. , 1975, Annual review of medicine.
[60] L. Aiello,et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.
[61] Y. Zou,et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.
[62] H. Ha,et al. Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. , 2000, Kidney international. Supplement.
[63] V. Gopalakrishnan,et al. Endothelin: emerging role in diabetic vascular complications , 1999, Diabetologia.
[64] A. Veves,et al. Endoneurial localisation of microvascular damage in human diabetic neuropathy , 1993, Diabetologia.
[65] A. Cerami,et al. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. , 1984, Annals of internal medicine.
[66] L. Dekker,et al. Protein kinase C-beta contributes to NADPH oxidase activation in neutrophils. , 2000, The Biochemical journal.
[67] D. Tomlinson. Mitogen-activated protein kinases as glucose transducers for diabetic complications , 1999, Diabetologia.
[68] A. Cerami,et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.
[69] H. Lum,et al. Oxidant stress and endothelial cell dysfunction. , 2001, American journal of physiology. Cell physiology.
[70] E. Ritz,et al. Nephropathy in patients with type 2 diabetes mellitus. , 1999, The New England journal of medicine.
[71] M. Meier,et al. Protein kinase C activation and its pharmacological inhibition in vascular disease , 2000, Vascular medicine.
[72] R. Danis,et al. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. , 1998, Investigative ophthalmology & visual science.
[73] J. Baynes. Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.
[74] K. Sugimoto,et al. Diabetic neuropathy – a continuing enigma , 2000, Diabetes/metabolism research and reviews.
[75] E. Boyko,et al. Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. , 1999, Diabetes care.
[76] M. Steffes,et al. Effects of Sorbinil on Glomerular Structure and Function in Long-Term–Diabetic Rats , 1989, Diabetes.
[77] R. Klein,et al. The Wisconsin epidemiological study of diabetic retinopathy: a review. , 1989, Diabetes/metabolism reviews.
[78] E. Schiffrin,et al. Vascular biology of endothelin. , 1998, Journal of cardiovascular pharmacology.
[79] H. Utsumi,et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. , 2000, Diabetes.
[80] S. Bursell,et al. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. , 1996, Investigative ophthalmology & visual science.
[81] J. Kreisberg,et al. The glomerular mesangium in diabetes mellitus. , 1993, Kidney international.
[82] H. Dvorak,et al. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. , 1986, Cancer research.
[83] N. Hotta,et al. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. , 1996, Biochemical and biophysical research communications.
[84] G. King,et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[85] G. Dibona,et al. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. , 2000, Diabetes.
[86] W. J. Litchy,et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohort , 1993, Neurology.
[87] S. Yusuf,et al. Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.
[88] W. Benedict,et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. , 1999, Science.
[89] Y. Akai,et al. Quantification of glomerular TGF-β1 mRNA in patients with diabetes mellitus , 1996 .
[90] G. King,et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. , 1997, The Journal of clinical investigation.
[91] L. Aiello,et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. , 1996, The Journal of clinical investigation.
[92] A. Kashiwagi,et al. Impaired Activation of Glucose Oxidation and NADPH Supply in Human Endothelial Cells Exposed to H2O2 in High-Glucose Medium , 1995, Diabetes.
[93] A. Malik,et al. Protein kinase C β1 overexpression augments phorbol ester‐induced increase in endothelial permeability , 1996, Journal of cellular physiology.
[94] N. Holbrook,et al. Oxidative Stress-induced Phospholipase C-γ1 Activation Enhances Cell Survival* , 2001, The Journal of Biological Chemistry.
[95] P. Campochiaro,et al. Retinal and choroidal neovascularization , 2000, Journal of cellular physiology.
[96] E. Schulze-Lohoff,et al. Regulation of mesangial cell function by vasodilatory signaling molecules. , 2001, Cardiovascular research.
[97] L. Aiello,et al. Diabetic eye disease. , 1996, Endocrinology and metabolism clinics of North America.
[98] P. Parker,et al. The extended protein kinase C superfamily. , 1998, The Biochemical journal.
[99] S. Jain,et al. Effect of glycemic control, race (white versus black), and duration of diabetes on reduced glutathione content in erythrocytes of diabetic patients. , 1994, Metabolism: clinical and experimental.
[100] K. Sharma,et al. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. , 1994, The Journal of clinical investigation.
[101] A. Bird,et al. The genetics of complex ophthalmic disorders. , 1996, The British journal of ophthalmology.
[102] M. Cooper,et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. , 1999, Diabetes.
[103] M. Matsumura,et al. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. , 2001, American journal of ophthalmology.
[104] B. Tesfamariam. Selective impairment of endothelium‐dependent relaxations by prostaglandin endoperoxide , 1994, Journal of hypertension.
[105] R. Griffey,et al. Diabetic neuropathy. Structural analysis of nerve hydration by magnetic resonance spectroscopy. , 1988, Journal of the American Medical Association (JAMA).
[106] A. Krolewski,et al. Polymorphisms of human paraoxonase 1 gene (PON1) and susceptibility to diabetic nephropathy in Type I diabetes mellitus , 2000, Diabetologia.
[107] A. Reddi,et al. Transforming Growth Factor-β1 Enhances Glomerular Collagen Synthesis in Diabetic Rats , 1993, Diabetes.
[108] N. Perico,et al. Atrial Natriuretic Peptide and Prostacyclin Synergistically Mediate Hyperfiltration and Hyperperfusion of Diabetic Rats , 1992, Diabetes.
[109] L. Oberley. Free radicals and diabetes. , 1988, Free radical biology & medicine.
[110] E. Schleicher,et al. Structural and functional changes in diabetic glomerulopathy. , 1996, Kidney & Blood Pressure Research.
[111] T. Hohman,et al. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. , 1989, Investigative ophthalmology & visual science.
[112] A. Windebank,et al. Capillary number and percentage closed in human diabetic sural nerve. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[113] J. Isner,et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. , 2001, The Journal of clinical investigation.
[114] F. DeRubertis,et al. Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. , 2001, Diabetes.
[115] S. Tesfaye,et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy , 2001, Diabetologia.
[116] G. Paolisso,et al. Oxidative Stress and Diabetic Vascular Complications , 1996, Diabetes Care.
[117] F. DeRubertis,et al. Antioxidant inhibition of protein kinase C-signaled increases in transforming growth factor-beta in mesangial cells. , 1997, Metabolism: clinical and experimental.
[118] Y. Nishizuka. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. , 1992, Science.
[119] D. Yue,et al. The Effect of Aldose Reductase Inhibition on Motor Nerve Conduction Velocity in Diabetic Rats , 1982, Diabetes.